NEW YORK (GenomeWeb News) – Nanosys and Harvard University have licensed certain patents and patent applications to Vista Therapeutics covering the use of nanowires for biosensors.

Under terms of the license, Louisville, Ky.-based Vista has received exclusive, worldwide rights to use nanowires for detection of biomarkers associated with organ or tissue damage, as well as any form of treatment-associated adverse response. In return, Harvard and Nanosys have received an undisclosed equity stake in Vista, upfront license fees, and will receive downstream royalty payments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.